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Abstract (< 150 words) 
Cancer cells often secrete extracellular vesicles (EVs) that carry heat shock proteins 
(HSPs) with roles in tumor progression. Oral squamous cell carcinoma (OSCC) belongs to 
head and neck cancers (HNC) whose lymph-node-metastases often lead to poor prognosis. 
We have examined the EV proteome of OSCC cells and found abundant secretion of 
HSP90-enriched EVs in lymph-node-metastatic OSCC cells. Double knockdown of HSP90α 
and HSP90β, using small interfering RNA significantly reduced the survival of the 
metastatic OSCC cells, although single knockdown of each HSP90 was ineffective. Elevated 
expression of these HSP90 family members was found to correlate with poor prognosis of 
HNC cases. Thus, elevated HSP90 levels in secreted vesicles are potential prognostic 
biomarkers and therapeutic targets in metastatic OSCC. 
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INTRODUCTION 
Oral squamous cell carcinoma (OSCC) accounts for approximately 3% of all human 
malignancies and for 24% of all head and neck cancers (HNCs) and is trending upward 
yearly [Jemal et al., 2011]. Regardless of recent advancements in many therapeutic 
strategies, OSCC remains associated with recurrence and progression. More than 50% of 
OSCC patients exhibit lymph node metastasis, one of the most common adverse prognostic 
factors in OSCC patients [Kowalski and Sanabria, 2007; Sano and Myers, 2007]. The 5-year 
survival rate of primary OSCC patients is greater than 80% but it falls to 40% with cervical 
lymph node metastasis and falls to 20% with distant metastases [Neveille and Day, 2002]. 
Cancer progression is often associated with extracellular molecules released by cancer 
cells into the milieu [Stivarou and Patsavoudi, 2015]. Such secreted molecules can educate 
cells in autocrine, paracrine and/or endocrine manners, thus inducing changes in tumoral, 
stromal, endothelial, immune/inflammatory, and distant cells. Extracellular vesicles (EVs) 
are surrounded by lipid bilayer membranes and contain a variety of cargos such as 
proteins, nucleic acids, lipid, and minerals [Colombo et al., 2014; Fujita et al., 2016; Pan et 
al., 1985; Skog et al., 2008]. It has been shown that cargos of EVs can be often transported 
to recipient cells where they exert their functions [Valadi et al., 2007]. According to vesicle 
size, EVs are classified as exosomes (30 to 200 nm), microvesicles (MVs) (100 to 1,000 
nm), apoptotic bodies (1,000 to 5,000 nm), and matrix vesicles (found in extracellular 
matrices and carrying abundant minerals) [Lotvall et al., 2014; Raposo and Stoorvogel, 
2013; Shapiro et al., 2015; Witwer et al., 2013]. EVs, in particular exosomes usually 
contain tetraspanins including CD9 [Andreu and Yanez-Mo, 2014] and cancer exosomes 
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often contain epithelial cell adhesion molecule (EpCAM) [Madhavan et al., 2015; Munz et 
al., 2009]. We showed highly surviving cancer stem-like cells to robustly secrete 
EpCAM-contained EVs [Eguchi et al., 2018b]. It was also shown that levels of epidermal 
growth factor (EGFR) were elevated in serum EVs as well as primary tumors in patients 
suffering from head and neck squamous cell carcinoma [Overmiller et al., 2017]. Notably, 
HSP90 was also found in EVs secreted by cancer cells [Clayton et al., 2005; Eguchi et al., 
2018b]. 
 HSP family members are molecular chaperones that bind loosely to de novo 
translated proteins or structurally unfolded proteins and promote folding or refolding of 
proteins that acquire physiological functions or induce proteasomal or lysosomal 
degradation of proteins [Murshid et al., 2013]. It has been reported that HSPs are 
overexpressed in various cancer tissues, correlating with disease incidence, progression 
and lymph node metastasis rate [Ciocca and Calderwood, 2005; Ciocca et al., 1993; Eguchi 
et al., 2018a; Gong et al., 2015]. The HSP family is composed of subfamilies including 
HSP70 family, HSP90 family, small HSP family (HSP27 family, HSPB family), and large HSP 
family (HSP105 / HSP110 family). Among these subfamilies, HSP90 is one of the major 
intracellular molecular chaperones and plays a role in interacting with various 
intracellular proteins to ensure its correct folding and function [Workman et al., 2007]. 
HSP90 can promote tumor growth and metastasis in breast cancer, leukemia, pancreatic 
cancer and ovarian cancer [Ciocca et al., 1993; Neckers and Workman, 2012]. HSP90 is 
composed of a number of proteins including cytoplasmic HSP90α, an inducible type, and 
HSP90β, a constitutively expressed type as well as mitochondrial TRAP1. Although their 
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expression levels increase under stressed condition and in cancer cells, HSP90β is one of 
the most abundant proteins in the cytoplasm of unstressed cells. HSP90 proteins act in an 
ATP-dependent manner as essential factors for the client protein to function properly in 
the cytoplasm in response to signals, in cooperation with co-chaperones including CDC37 
[Calderwood, 2015]. Many of the proteins folded by HSP90-CDC37 complexes are  
involved in cell growth, and the HSP90-CDC37 complex is an attractive candidate for 
cancer chemotherapy [Calderwood, 2015; Neckers and Workman, 2012]. In addition to 
their intracellular roles, HSP-contained EVs and EV-free HSPs have been also found in the 
extracellular space [Clayton et al., 2005; Eguchi et al., 2018b; Li et al., 2013].  
In the present study, we have investigated the EV chaperonome of metastatic OSCC cells, 
which is involved in cancer cell survival and thus prognosis of OSCCs. 
 
MATERIALS AND METHODS 
Cell culture 
HSC-3 OSCC cell line and its metastatic subline HSC-3-M3 [Matsui et al., 1988] were 
obtained from JCRB cell bank at National Institutes of Biomedical Innovation, Health, and 
Nutrition. For maintenance, these cell lines were cultured in DMEM containing 10% FBS, 
and the medium was replaced in every 3 days. 
 
Isolation of EVs 
We compared the polymer-based precipitation (PBP) method as described [Eguchi et al., 
2018b] and the ultracentrifugation (UC) method [Lotvall et al., 2014; Witwer et al., 2013] 
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to isolate EVs, as shown in a flow chart (Fig. S1A). Cells growing in two 10-cm dishes were 
washed with Hanks’ balanced salt solution (HBSS), and then further cultured in 4 ml of 
serum-free medium per a dish for 2 days. Cell culture supernatant was centrifuged at 
2,000 × g for 30 min at 4°C to remove detached cells. The supernatant was then 
centrifuged at 10,000 × g for 30 min at 4°C to remove cell debris. In addition, the 
supernatant was filtered with a 0.2-μm syringe filter. In the PBP method, the supernatant 
(8 ml) was concentrated to less than 1 ml by using an Ultra-15 Centrifugal Filter Devices 
for MW. 100,000 (Amicon). The concentrate was applied to Total Exosome Isolation 
(ThermoFisher Scientific). The EV fractions were eluted in 100 μl PBS (-). In the UC 
method, 8 ml of the supernatant was centrifuged at 100,000 × g for 70 min (RP-42 rotor, 
Hitachi). Total EVs pellets were rinsed in PBS (-), centrifuged at 100,000 × g for 70 min 
and suspended in 100 μl of PBS (-). For protein assay, 10 μl of 10 × RIPA buffer containing 
10% NP-40, 1％ SDS, and 5％ deoxycholate in PBS (-) and a EDTA-free protease inhibitor 
cocktail (Sigma) were added to the 100 μl of the EV fraction and incubated on ice for 30 
min. Thirty-five microliter of the EV was used for protein assay using micro BCA protein 
assay system (ThermoFisher Scientific). 
 
Transmission electron microscopy (TEM) 
As described [Eguchi et al., 2018b]. A 400-mesh copper grid coated with formvar / carbon 
films was hydrophilically treated. The EV suspension (5 to 10 μl) was placed on Parafilm, 
and the grid was floated on the EV liquid and left for 15 min. The sample was negatively 
stained with 2% uranyl acetate solution for 2 min. EVs on the grid were visualized with 
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20,000 times magnification with an H-7650 transmission electron microscope (Hitachi, 
Tokyo, Japan) at Central Research Laboratory, Okayama University Medical School.  
To determine the EV sizes, lengths of the major axes of 50 EVs between 50 nm and 200 
nm-diameters in the TEM images were measured. To examine statistical homoscedasticity 
of those 2 groups, F-test was performed with a null hypothesis that variances of those 2 
groups were equal. Paired Student’s t-test was then performed. 
 
Particle diameter analysis 
Forty μl of EV fraction within PBS (-) was used. Particle diameters of the EV fractions in a 
range between 0 and 1,000 nano-diameters were analyzed in Zetasizer nano ZSP (Malvern 
Panalytical, UK). 
 
ExoScreen 
ExoScreen was performed as described [Yoshioka et al., 2014]. Serial dilution standards of 
exosome were prepared from a 50 ng/μl of CD9 positive exosome fraction prepared from 
HCT116 cells. PBS (-) was used for a negative control. For CD9 positive exosome 
ExoScreen, 5 μl of EV fraction was mixed with 20 μl of a mixture of acceptor beads 
immobilized with anti-CD9 antibodies and biotinylated anti-CD9 antibodies in a white 
96-well plate. The plate was centrifuged briefly and was shaken with a vortex. The 
samples were incubated at room temperature (RT) for 1 h with avoiding light. Then, 25 μl 
of 80 μg/ml streptavidin-immobilized donor beads were added. The plate was centrifuged 
briefly, and vortex. The samples were incubated at RT for 30 min without light. After 
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adding excitation light (wave length 680 nm), the light of emission (wave length 615 nm) 
was measured in EnSpire AlphaLISA system (PerkinElmer). ExoScreen was performed 
with duplicate per each EV fraction. For analysis of CD9-EpCAM double positive exosome, 
5 ng/μl CD9-EpCAM standard protein and its step dilution were used for standard, and 
acceptor beads immobilized with anti-CD9 antibodies and biotinylated anti-EpCAM 
antibodies were used. The samples were measured with duplicate in the 
ExoScreen-AlphaLISA system.  
 
Whole cell lysate 
As described [Eguchi et al., 2018b]. Cells cultured on a 10-cm dish were washed with 5 ml 
of PBS (-) and then collected by using a cell scraper and centrifuged for 5 min at 4 °C at 
1,000 × g. The cells were washed with PBS (-) and centrifuged again. Then, 1000 μl of a 1 × 
RIPA buffer containing 1% NP-40, 0.1％ SDS, and 0.5％ deoxycholate in PBS (-) and 
protease inhibitors were added to the cellular pellet. Cells were then lysed through a 
25-gauge syringe for 10 strokes. The cell lysate was incubated for 30 min on ice and then 
centrifuged at 15,000 × g for 20 min at 4 °C to pellet cell debris. The supernatant was used 
as a whole cell lysate (WCL). The WCL was diluted 10-fold, and protein concentration was 
measured by using micro BCA protein assay system (ThermoFisher Scientific). 
 
Western blotting analysis 
As described [Eguchi et al., 2018b]. Equal amounts of protein samples in each Western 
blotting analysis (each 4 μg of protein samples for analysis of CD9, EpCAM, HSP90α and 
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β-actin, and each 10 μg of protein samples for analysis of EGFR, HSP90β and GAPDH) were 
separated by SDS-PAGE in in 4-20% TGX-GEL (BioRad) and transferred to PVDF 
membranes by using a semi-dry method. The membranes were blocked in Tris-buffered 
saline (TBS) containing 0.05% Tween 20 (TBS-T) and 5% ECL Blocking Agent (GE 
Healthcare) for 1 h with shaking at RT. Each membrane was incubated overnight with 
shaking at 4˚C with primary antibodies: either mouse anti-CD9 (1:1,000, MBL), mouse 
anti-EpCAM (1:1,000, Cell signaling technologies), rabbit anti-HSP90α (1:5,000, GeneTex), 
rabbit anti-HSP90β (1:1,000, GeneTex), or rabbit anti-EGFR (1:1,000, Abcam). Afterwards, 
horseradish peroxidase (HRP)-conjugated anti-mouse IgG (1:10,000, cell signaling 
technologies) or anti-rabbit IgG (1:10,000, GE Healthcare) secondary antibodies were 
incubated for 1 h with shaking at RT. Washes before and after antibody reactions were 
done on a shaker, three times within TBS-T for 10 min at RT. Alternatively, membranes 
were incubated with HRP-conjugated mouse anti-β-actin (1:5,000, Wako) or anti-GAPDH 
(1:10,000, Wako) antibodies for 1 h with shaking at RT. Blots were visualized with a ECL 
Plus Western blotting substrate (Pierce). 
 
Mass spectrometry 
Liquid chromatography and tandem mass spectrometry (LC-MS/MS) was carried out as 
described previously [Eguchi et al., 2008]. The EV fractions were used for short SDS-PAGE 
(approx. 4 mm) in 4-20% TGX-GEL (BioRad) and visualized with Coomassie Brilliant Blue 
stain (BioRad). Gel fragments containing the stained protein bands were excised, then 
minced into 1 × 1 to 2 × 2 mm pieces. The proteins were digested by using In-Gel Tryptic 
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Digestion Kit (ThermoFisher Scientific). The gel pieces were destained with mixture of 
ammonium bicarbonate and acetonitrile. The protein samples were reduced with 50 mM 
Tris [2-carboxyethyl] phosphine (TCEP), and alkylated with iodoacetamide (IAA). In order 
to shrink gel fragments, acetonitrile was added and incubated for 15 min at RT after which 
the acetonitrile was removed and the gel pieces were air dried for 5-10 min. Ten 
microliter of MS grade trypsin (Pierce) at concentration of 0.1 mg/ml was added to the 
air-dried sample and incubated at RT for 15 min. Ammonium bicarbonate at a final conc. 
of 25 mM was added to the sample, digested overnight at 30 °C, and the extract was 
recovered. Subsequently, a 1% formic acid solution was added to the gel pieces, incubated 
for 5 min, and the supernatant was added to the extract. Extracts containing digested 
peptides were measured by Agilent 6330 Ion Trap LC / MS System with MASCOT database 
search engine at Central Research Laboratory, Okayama University Medical School. The 
cutoff score for proteins was 11.0. The score was defined based on the covering rate for 
amino acid sequences and the frequency of detected fragments. The data of MS were 
analyzed as described previously by using 2-Dimensional Image-Converted Analysis of 
LC-MS/MS (2DICAL2) software (Mitsui Knowledge Industry, Tokyo, Japan) [Ono et al., 
2012]. The detected protein species were collated with the ExoCarta database 
[Mathivanan et al., 2012]. Among the protein species detected in the EVs of each cell line, 
the top 50 protein species were selected with reference to the MS score. Protein species 
specifically detected in each EV fraction were classified according to their biological 
function and compared based on the number of protein species or MS score. 
 
Page 11 of 79
John Wiley & Sons, Inc.
Journal of Cellular Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
 
Prognostic values of HSP genes expression in tumor samples resected from HNC 
patients 
To examine prognostic values of HSP gene expression in clinical samples of HNCs, we 
retrieved The Human Protein Atlas [Uhlen et al., 2015]. HNCs patients (n = 499) were 
distinguished between high expression group and low expression group in each gene. 
Correlation between gene expression levels and prognosis of patients were shown as 
Kaplan-Meier survival analyses. The high- or low-expression group was examined at each 
stage of HNC (stage 1: n = 25, stage 2: n = 69, stage 3: n = 78, stage 4: n = 259). The ratio 
(high expression group / low expression group) was calculated for each stage, and the 
correlation between gene expression level and stage progress of HNC was examined. 
 
RNAi 
We designed siRNA species that target each mRNA coding HSP90α, HSP90β, and CDC37 
individually (Table S1). The synthesized siRNA was RNA duplex of 19 bp plus TT-3’ 
overhangs in each strand. For targeting each mRNA, a mixture of two types of siRNA were 
used. 
 
Electroporation-transfection 
Electroporation was performed using NEPA21 electroporator (NEPA Gene, Ichikawa, 
Japan) according to the manufacturer's recommendation. HSC-3-M3 cells (5 × 105 cells) 
were centrifuged at 1,000 × g for 5 min at RT and suspended in 100 μl of serum-free 
DMEM with 40 pmol siRNA. Poring pulse condition was 250 V, 1.5 milliseconds (ms) pulse 
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length, total two pulses, 50 ms interval between the pulses, and 10% decay rate with + 
polarity. The transfer pulse condition was 20 V, 50 ms pulse length, total five pulses, 50 ms 
interval among the pulses, 40% decay rate with +/- polarity. After the electroporation, 
cells were immediately suspended into DMEM containing 10% FBS and seeded at 
concentration of 5 × 105 cells / 2 ml in a well of 6-well plates. Three days after the 
electroporation, cells were harvested for cell counting and Western blotting. 
 
Cell survival 
Cells were transfected with siRNA using electroporation and then seeded as described 
above. Cells were washed with PBS (-) at 24 hours after the transfection and further 
cultured in 2 ml of DMEM containing 10% FBS per a well for 2 days. Cells were detached 
using Trypsin/EDTA at 3 days post-transfection period and number of cells were counted 
using Countess® Automated Cell Counter (ThermoFisher Scientific). Photomicrographies 
were taken using Floid® Cell Imaging Station (ThermoFisher Scientific). 
 
Statistical analysis 
Statistical significance was calculated using Microsoft Excel. Difference of two sets of data 
were examined with a paired Student's t-test. P < 0.05 was considered to indicate 
statistical significance. Data were expressed as means ± S.D. unless otherwise specified. 
 
RESULTS 
Preparation of EVs using the PBP method and the UC method 
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Several methods for EV preparation have been established as follows: UC method, PBP 
[Eguchi et al., 2018b], affinitiy capturing [Nakai et al., 2016], sucrose density gradient, size 
exclusion chromatography, filtration, immunological separation, isolation by sieving, and 
their combinations [Lobb et al., 2015; Lotvall et al., 2014; Witwer et al., 2013]. These 
methods have distinctive mechanism of EV preparation with advantages and 
disadvantages. We in the present study tested PBP and UC methods for isolation of EVs 
from culture supernatants of HSC-3 OSCC cell line and its metastatic subline HSC-3-M3 
(Fig. S1 A). Particles sized between 50 and 200 nm-diameters with cup-shaped 
morphology were found in the EV fraction prepared by using the PBP method, suggesting 
exosomes and/or MVs (Fig. S1 B, upper TEM images). A few EV-like particles were also 
found in the EV fraction isolated by the UC method (Fig S1 B, lower TEM images). To 
examine EV collection efficiency, we next measured protein concentration of EVs. The 
ratio of EV protein concentration per the cellular protein concentration was 
approximately 3.0% in the PBP method-used EVs whereas it was approximately 1.5% in 
the UC method-derived EVs, suggesting that EVs were more efficiently collected using the 
PBP method. We therefore used the PBP method for preparation of EVs in the following 
studies. 
 
The metastatic OSCC cells secrete larger EVs compared to those secreted by parental 
OSCC cells. 
We prepared EVs from culture supernatants of HSC-3 and HSC-3-M3 cells by using the PBP 
method shown above and analyzed their morphological difference of EVs under TEM. EVs 
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with a cup-shaped morphology were found in EV fractions of both HSC-3 and HSC-3-M3 
cells, indicating that both cell lines secrete exosomes and/or MVs (Fig. 1 A, B).  
 It has been shown that the sizes of exosomes are present in a range between 50 
and 200 nm-diameters while those of MVs are between 100 and 500 nm [Colombo et al., 
2014; Fujita et al., 2016]. To investigate if the OSCC cells secrete exosomes, we next 
examined the sizes of EVs in the range between 50 and 200 nm secreted by metastatic and 
parental OSCC cells. Vesicles sized between 50 and 200 nm were found in the EV fractions 
of both cell types, which were suggested to secrete exosomes. The median and mean of the 
diameters of HSC-3-M3-derived EVs (109 nm and 111.8 nm, respectively) were 
significantly larger than those of HSC-3-derived EVs (80.7 nm and 94.6 nm, respectively), 
indicating that HSC-3-M3 secreted larger EVs than HSC-3 (Fig. 1 C).  
 To investigate whether these OSCC cells secrete MVs in addition to exosomes, 
we next analyzed particle diameter distributions of the EVs. Both cell types secreted EVs 
with single peaks, indicating that these EV fractions had some homogeneity (Fig 1 D, E). 
The HSC-3-EVs were sized in a range between 50 and 450 nm-diameters whereas the 
HSC-3-M3-EVs were sized in a range between 50 and 500 nm-diameters, suggesting that 
the metastatic cells might secrete more MVs (Fig 1 D, E). Consistently, the size peak of 
HSC-3-EVs was found at 155.1 nm whereas that of HSC-3-M3-EVs was shifted to 167.1 nm 
(Fig. 1 D, E).  
 These results indicated that the metastatic OSCC cells secrete larger EVs than 
those derived from the parental OSCC cells. 
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Metastatic OSCC cells secrete more EpCAM-EVs than their parental OSCC cells 
We next examined levels of CD9, which is generally contained in most exosomes, and 
EpCAM, which is more often found in cancer exosomes. CD9 and EpCAM were present in 
HSC-3-M3-EVs at higher levels than in the parental cells-derived EVs (Fig 2A). The 
elevated levels of EpCAM and CD9 in HSC-3-M3-EVs were found using both PBP and UC 
methods with similar tendnecies.  
 We next examined CD9 positive exosomes and CD9-EpCAM double positive EVs 
using ExoScreen, a sensitive and rapid analytical system with two types of antibodies that 
capture EVs and detect the presence of exosomes with photosensitizer-beads [Yoshioka et 
al., 2014]. HSC-3-M3 cells secreted more CD9 positive exosomes than HSC-3 cells: levels of 
CD9 positive exosomes per EV fraction were and 4.5% (HSC-3) and 8.2% (HSC-3-M3), 
respectively (Fig. 2B). The CD9 positive exosome concentration was 360 ng per 106 cells 
(HSC-3) and 640 ng per 106 cells in HSC-3-M3 (Fig. 2C), consistent with the data from 
Western blotting shown above. 
 We next examined the levels of CD9-EpCAM double positive exosomes (v/w % 
per EV fraction and ng per 106 cells) in the two cell lines. HSC-3-M3 cells secreted more 
CD9-EpCAM double positive exosomes than HSC-3 cells: CD9-EpCAM double positive 
exosomes per EV fraction were 2.8% (HSC-3) and 3.6% (HSC-3-M3), respectively (Fig. 2D). 
CD9-EpCAM double positive exosomes (ng) per 106 cells was 220 ng per 106 cells (HSC-3) 
and 275 ng per 106 cells (HSC-3-M3), respectively (Fig. 2E), consistent with the data from 
Western blotting shown above. 
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 These results suggested that the EpCAM level in exosomes could be a potential 
biomarker of lymph-node-metastatic OSCC cells. 
 
The metastatic OSCC cells profoundly secrete HSP90-EVs. 
To characterize the metastatic OSCC cells and their EVs, we next examined whether HSP90, 
EpCAM, EGFR, GAPDH, and β-actin were contained in the EVs that were secreted by HSC-3 
and HSC-3-M3. The level of HSP90α was profoundly higher in the HSC-3-M3-EVs and in 
the HSC-3-M3 cells as compared to those of HSC-3, suggesting that HSP90α increased in 
this metastatic type of OSCC cells that then abundantly secreted HSP90α-EVs (Fig 3, top). 
Of note, HSP90β was specifically found in the HSC-3-M3-EVs but not in the HSC-3-EVs 
while cellular HSP90β was reduced in HSC-3-M3 as compared to the parental cells, 
suggesting that metastatic OSCC cells can selectively secrete HSP90β-EVs that may be 
involved in the metastatic phenotype (Fig 3, the second from the top). 
 We next examined levels of EpCAM and EGFR trans-membrane oncoproteins in 
the EVs and cells. EpCAM was profoundly at a high level in the HSC-3-M3-EVs as compared 
to the HSC-3-EVs while cellular EpCAM was reduced in HSC-3-M3 as compared to the 
parental cells, suggesting that metastatic OSCC cells can actively secrete EpCAM-EVs that 
may involve metastatic phenotype (Fig 3, the third from the top). Most EGFR appeared to 
be retained in these OSCC cells, although HSC-3-M3 secreted EGFR-EVs more than HSC-3 
cells.  
 Housekeeping proteins such as GAPDH and β-actin have been also found in EVs 
[Durcin et al., 2017; Mathivanan and Simpson, 2009]. The levels of GAPDH and β-actin 
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were not altered between HSC-3-M3 and HSC3 and between their EV fractions, suggesting 
that these housekeeping proteins may be useful as loading controls in analysis of EVs as 
well as cell lysates. 
 These results indicate that metastatic OSCC cells can robustly secrete 
HSP90-EVs and EpCAM-EVs that may involve their metastatic phenotype. Another 
inference to be drawn from this data is that the levels of proteins found in the cytoplasm 
do not necessarily predict their levels in EVs (Fig. 3). Relative levels of Hsp90α and EpCAM 
are relatively high compared to their intracellular concentrations while the opposite is 
true for Hsp90β, GAPDH and EGFR (Fig. 3). 
 
A proteome signature of OSCC-EVs 
To characterize OSCC cells and their EVs, we next analyzed the EV proteomes of HSC-3-M3 
and HSC-3 by mass spectrometry. Within the prepared EV fractions, total 192 protein 
species were identified commonly between in HSC-3-EVs and HSC-3-M3-EVs (Fig. 4A). To 
examine whether these EVs contained known and novel EV proteins, we next compared 
these OSCC-EV proteins with EV proteins registered in the ExoCarta database [Mathivanan 
et al., 2012]. Among the 192 protein species in the OSCC-EVs, 108 EV protein species 
(56.3%) were already registered in ExoCarta and 84 EV protein species (43.7%) were not 
registered yet and thus potentially novel EV proteins (Fig. 4A).  
 To characterize the metastatic phenotype of OSCC cells associated with their 
EVs, we next compared the nature of the top 50 EV protein species between the 
HSC-3-M3-EVs and HSC-3-EVs. Thirty two percentage of the EV protein species was 
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distinct for each of the cell types, suggesting that these specific proteins could play a role 
in metastatic phenotype within the two cell lines (Fig. 4B). To further characterize 
differences in the proteomes, we next classified the top 16 EV protein species according to 
their known functions. The functioal classification of EV proteins revealed that the 
HSC-3-M3-EVs carried more molecular chaperones and cytoskeletal proteins, and less 
extracellular matrix (ECM) proteins than HSC-3-EVs (Fig. 4 C, D).  
 We next investigated the molecular chaperone species in these OSCC-EVs. 
Among the total 192 EV protein species, 14 types of molecular chaperones were identified 
and 9 of them were specifically at high levels in HSC-3-M3-EVs as compared to HSC-3 EVs 
(Fig. 4E). The MS score ratios for the molecular chaperones (HSC-3-M3 / HSC-3) were 1.78 
(HSP90α), 2.23 (HSP90β), 2.95 (TRAP1, mitochondrial HSP90), and 1.78 (HSP105 / 
HSPH1), respectively (Table 1) (It was confirmed by western blotting analysis that 
HSP90-enriched EVs were secreted by the metastatic OSCC cells line as shown in Table S2 
and Fig 3). 
 It was thus suggested that lymph-node-metastatic OSCC cells secreted EVs 
enriched in particular HSPs, which could be thus useful markers for prognosis of OSCC 
cases.  
 
Prognostic values of HSP gene expression in clinical tumor samples of head and 
neck cancers 
As levels of HSPs in EVs likely reflect their relative intracellular expression, we 
investigated correlation between HSP gene expression levels in tumors and prognosis of 
Page 19 of 79
John Wiley & Sons, Inc.
Journal of Cellular Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
20 
 
patients suffering from HNCs. We examined clinical values of HSP90AA1 (coding HSP90α), 
HSP90AB1 (coding HSP90β), TRAP1 (coding mitochondrial HSP) and HSPH1 (coding 
HSP105) genes by using The Human Protein Atlas [Uhlen et al., 2015]. HNC patients were 
distinguished between high and low expression groups for each gene and survival rates 
were compared using Kaplan-Meier analysis. The 5-year survival rate of each chaperone 
high expression group of HSP90AA1, HSP90AB1, TRAP1, and HSPH1 was lower than that of 
each low expression group, respectively (Fig. 5, Table S3), indicating that high expression 
of these HSPs could be correlated to poor prognosis of HNCs. In particular, the ratio (high 
expression group / low expression group) valued by HSP90AA1 expression level in stage 1 
(n = 25) of HNCs was 0.39 whereas that in stage 4 (n = 259) was 1.21, indicating that 
HSP90AA1 expression could increase along with progression of HNCs (Table 2). The ratio 
valued by HSP90AB1 expression level in stage 1 of HNCs was 0.14 whereas that in stage 4 
was 0.57 (Table 2). The ratio valued by TRAP1 expression level in stage 1 of HNCs was 
2.57 whereas that in stage 4 was 4.18 (Table 2). Thus, these three genes increased the 
proportion of the high expression group as the stage of HNC progressed. In contrast, the 
ratio valued by HSPH1 expression level in stage 1 of HNCs was 3.17 whereas that in stage 
4 was 2.20 (Table 2). 
 These data suggest that high expression of HSP90AA1, HSP90AB1, and TRAP1 
are potentially useful for prognosis of HNC patients. It should be kept in mind in vewing 
the data that the relationship between intracellular gene expression and secretion in EV 
can be complex (Fig. 3). However increased intracellular expression of HSPs is likely to 
lead to greater release in EVs. The relative roles of intracellular and extracellular 
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chaperones in cancer is currently under assessment and their relative significance still 
under debate [Calderwood, 2018]. 
 
Double knockdown of HSP90α and HSP90β declined survival of metastatic OSCC 
cells 
We next examined whether siRNA-mediated knockdown of HSP90 could alter survival of 
metastatic OSCC cells. The siRNA targeting of HSP90α lowered the HSP90α level but did 
not lower survival of HSC-3-M3 cells. The siRNA targeting of HSP90β slightly lowered the 
HSP90β level as well as survival of HSC-3-M3 cells (Fig. 6). Of note, siRNA double targeting 
of HSP90α and HSP90β profoundly lowered HSP90β and HSP90α levels and significantly 
lowered survival of HSC-3-M3 cells as compared to the single knockdown effect (Fig. 6). 
We next examined involvement of CDC37, a co-chaperone of HSP90 in the cell survival 
studies. Interestingly, CDC37 level was reduced by knockdown of either HSP90α or 
HSP90β but not by double knockdown of HSP90α/β, suggesting that this co-chaperone 
could be destabilized upon reduction in the partner HSP90 but with potentially 
compensatory mechanism (Fig. 6). Triple knockdown of HSP90α/β and CDC37 also 
significantly lowered survival of metastatic OSCC cells (Fig. 6). 
 These findings indicate that the siRNA-mediated double targeting of HSP90α 
and HSP90β could be a potential therapeutic in metastatic OSCC. 
 
DISCUSSION 
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Metastatic and parental OSCC cells secreted EVs (Fig 1-3, Fig S1), although their relative 
sizes (Fig 1), levels of cancer EV markers (Fig 2, 3), EV proteome signatures (Fig 4), and EV 
chaperone signatures (Fig 3, 4, Table 1) were significantly different between these two 
types of cancer cells. It has been known that a size range of exosomes can be between 
approx. 50 and 200 nm-diameters whereas that of MVs can be between approx. 100 and 
500 nm [Raposo and Stoorvogel, 2013]. A single cell type such as platelets, endothelial 
cells, and breast cancer cells releases both exosomes and MVs [Heijnen et al., 1999]. The 
OSCC cells secreted EVs sized between 50 and 500 nm with a peak at approx. 160 nm, 
indicating that these EV fractions included exosomes and MVs (Fig 1 C-E). Interestingly, 
the sizes of EVs appeared to shift larger when the OSCC cells became transformed to a 
more metastatic phenotype (Fig 1 C-E). Simultaneously, the metastatic OSCC cells 
abundantly secreted EVs that contained oncogenic proteins, including EpCAM, EGFR and 
HSP90 (Fig 2-4). Such an oncogenic signature was more significant in the 
HSC-3-M3-derived EVs as compared to the HSC-3-EVs. In addition, TRAP1, a mitochondrial 
HSP, and HSP105 were significantly enriched in the EVs derived from metastatic OSCC 
cells (Table 1) and expression of these HSP genes was correlated with poor prognosis of 
HNCs (Fig 5, Table 2, Table S3). We hypothesize that EV proteins can reflect metastatic 
phenotype of cancer cells and thus can be potentially prognostic biomarkers in OSCC cases. 
We also showed that HSP90α was robustly expressed and secreted by cancer-stem like 
cells that survive under selective pressure [Eguchi et al., 2018b]. HSP90α level was also 
elevated in the metastatic OSCC cells and in their EVs (Fig 3, top). This result indicates that 
HSP90α was robustly expressed in the metastatic OSCC cells and then secreted within 
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their EVs (Fig 3, top). HSP90β significantly increased in the HSC-3-M3-EVs while 
intracellular HSP90β was reduced as compared to the parental cells (Fig 3, second from 
the top), suggesting that HSP90β-EVs can be a novel secretory phenotype of metastatic 
cancer cells. It has been shown that HSP90 can promote tumor growth and metastasis in 
breast cancer, leukemia, pancreatic cancer and ovarian cancer [Ciocca and Calderwood, 
2005; Ciocca et al., 1993; Neckers and Workman, 2012]. High-level expression of genes 
encoding HSP90α and HSP90β in clinical tumor samples were also correlated with poor 
prognosis of HNC cases and with higher stages of HNCs (Fig 5, Table 2). Targeting of 
HSP90 in cancer chemotherapy is currently a major area of research [Li et al., 2013; 
Neckers and Workman, 2012]. These chemicals directly target HSP90 proteins, in 
particular ATP binding and hydrolysis [Trepel et al., 2010] while the HSP90-siRNAs target 
mRNAs encoding HSP90α and HSP90β individually led to mRNA degradation. The 
siRNA-mediated double knockdown of HSP90α and HSP90β significantly reduced the 
survival of metastatic OSCC cells whereas each single knockdown showed lesser effects 
(Fig 6), suggesting a mutually compensatory system of these HSP90. The HSP90-siRNA 
could reduce cellular as well as exosomal HSP90 at mRNA and protein levels when 
administrated to EV-producing cancer cells. Moreover, siRNA species could be carried by 
EVs that transfer cargos into recipient cells in a similar way to EV transport of microRNA 
species. The HSP90-contained EVs may sustain survival and metastatic phenotypes of 
cancer cells in autocrine and paracrine manners. The siRNA-mediated targeting of HSP90 
can thus efficiently reduce these phenotypes of cancer cells. In addition, triple knockdown 
of the HSP90α/β and their co-chaperone CDC37 also significantly lowered survival of the 
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HSC-3-M3 cells and might be more effective than HSP90 double knockdown (Fig 6C). The 
mechanism by which chaperone-enriched EVs involve OSCC progression and metastasis is 
currently undertaken. 
 One of the interesting findings in the study was that levels of proteins in the EV 
are not necessarily predicated by their relative intracellular concentrations (Fig. 3). The 
relative behavior of Hsp90α and Hsp90β was typical in this way. Although intracellular 
Hsp90α levels appeared relatively lower than those of Hsp90β, secretion of the alpha 
isoform appeared to be considerably greater (Fig. 3). Indeed the extracellular functions of 
Hsp90α are of growing significance and mechanisms of secretion involving 
phosphorylation, ubiquitinylation and upstream activation by HIF1α have been proposed 
[Li et al., 2007; Sarkar and Zohn, 2012; Wang et al., 2009]. Such mechanisms may serve to 
enrich individual proteins in EV in a regulated manner. 
 In addition to these HSPs, the metastatic OSCC-derived larger EVs contained 
abundant cytoskeletal proteins, particular enzymes and less ECM proteins as compared to 
the smaller EVs that were secreted by parental cells (Fig 4). It was recently shown that 
adipocytes also secreted two types of EVs: large EVs that contained molecular chaperones 
and cytoskeletal proteins and smaller EVs containing ECM proteins [Durcin et al., 2017]. 
Thus, it may be a general finding that large EVs or MVs are enriched with chaperones and 
cytoskeletal proteins while small EVs or exosomes can be enriched with ECMs within 
particular cell types. Metastatic cancer cells may secrete chaperone-enriched enlarged EVs 
whereas benign tumors may secrete chaperoneless small EVs. We also showed that cancer 
cells produced intracellular matrix metalloproteinase 3 (MMP3) that can regulate gene 
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expression of chaperones and matricellular protein CCN2 [Eguchi et al., 2017; Eguchi et al., 
2010]. MMPs can regulate production and status of ECM-EVs. Therefore, roles and 
targeting of MMPs in regulation of EV are currently being undertaken. 
 In conclusion, metastatic oral cancer cells secrete extracellular vesicles that are 
enriched with molecular chaperones, including HSP90α and HSP90β. The HSP90, TRAP1, 
and HSP105 are potentially EV biomarkers of cancer metastatic phenotype as well as 
prognostic biomarkers in HNCs. 
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FIGURE LEGENDS 
Fig 1. EVs secreted by the metastatic oral cancer cells were larger than those 
secreted by the parental cells. (A, B) Representative TEM images of EVs secreted from 
the parental HSC-3 (A) and the metastatic HSC-3-M3 cells (B). Arrowheads indicate EVs 
with cup-shaped morphology. Scale bars, 200 nm. (C) Combined box-and-whisker and dot 
plots of EVs. Major axes of EVs were measured in TEM images. n = 50. *P = 0.045 (paired 
t-test). (D, E) Particle diameter distribution analysis of EVs secreted by (D) and HSC-3-M3 
cells (E).  
Fig 2. Metastatic OSCC cells secrete EpCAM-enriched EVs including exosomes more 
than the parental cells. Cells were cultured for 2 days in serum-free medium from which 
EV fractions were prepared. (A) Western blot showing EpCAM and CD9. EV fractions were 
prepared from HSC-3 and HSC-3-M3 cells using the polymer-based precipitation or 
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ultracentrifugation methods. Equal amounts of EV proteins were loaded into each lane. 
Representative data are shown. (B-E) The concentration of CD9 positive exosomes (B, C) 
or CD9-EpCAM double positive exosomes (D, E) v/w % per EV fraction (B, D) or secreted 
amount (ng) per 106 cells (C, E) were quantified by using ExoScreen.  
 
Fig 3. HSP90 and EpCAM increased in EVs released by lymph-node-metastatic OSCC 
cells. The EV and cellular fractions were prepared at the same time point after 2 days of 
serum-deprivation. Equal amounts of EV- or cellular proteins were used for each Western 
blotting analysis. HSP90α, HSP90β, EpCAM, EGFR, GAPDH and β-actin in the EVs and 
whole cell lysates were analyzed. M.W., molecular weight. 
 
Fig 4. EV proteomics and chaperonomics of OSCC cells. (A) Venn diagram comparing 
proteins in OSCC-EVs with proteins in ExoCarta database. Total 192 types of proteins were 
detected in EVs by the proteomics. ExoCarta database documented 6,514 proteins. Among 
the 192 protein species, 108 protein species (56.3%) found in the OSCC-derived EVs were 
already documented in the ExoCarta database, whereas 84 protein species (43.7%) were 
novel EV proteins. (B) Venn diagram comparing differential EV proteome signatures of 
HSC-3 and HSC-3-M3. Among top 50 EV protein species found in each cell line 34 protein 
species (68%) were common between the two EV fractions, whereas the remaining 16 
protein species (32%) were distinctive in each OSCC-EV fraction. (C, D) Functional 
properties of EV proteomes of the parental and the metastatic OSCC cells. Top 16 protein 
species in each EV fraction derived from HSC-3 and HSC-3-M3 were functionally 
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categorized, and numbers of protein species (C) and total MS scores (D) were distributed 
to each category. Molecular chaperones were found in HSC-3-M3-EV with high scores as 
compared to HSC-3-EVs. (E) Venn diagram comparing differential EV chaperones 
signatures of HSC-3 and HSC-3-M3. Among 14 EV chaperone species found in each cell line 
9 chaperones species (64%) were highly detected in HSC-3-M3, whereas only 1 chaperone 
specie (7%) was highly detected in HSC-3. 
 
Fig. 5. Prognostic values of HSPs in HNC cases. Kaplan-Meier survival analysis for 
HSP90AA1 (A), HSP90AB1 (B), TRAP1 (C) and HSPH1 (D) genes in HNCs were retrieved 
from The Human Protein Atlas. Expression values of each gene were divided into high 
(purple line) and low (blue line) expression using each best cut off value as the threshold 
value. P values correspond to the log-rank test comparing the survival curves.  
 
Fig 6. Targeting of HSP90 in metastatic OSCC cells. HSC-3-M3 cells were transfected 
with chaperone-targeting siRNA (siHSP90α, siHSP90β or siCDC37) or non-targeting 
dsRNA (siCtrl). (A) Western blot showing single, double and triple knockdown of HSP90α, 
HSP90β and CDC37 in HSC-3-M3 cells. Equal amounts of cellular proteins were used for 
each lane. (B) Survival of the HSC-3-M3 cells upon chaperone knockdown. Numbers of 
adherent cells 3 days after transfection of siRNA were shown. n = 3. *P < 0.05, **P < 0.01 
(paired t-test). (C) Representative photomicrographs of the cells at day 3 after 
transfection of siRNA. Scale bar, 100 μm. 
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Fig S1. Polymer-based precipitation method and ultracentrifugation method for 
preparation of EVs. (A) A workflow of the EV preparation methods. (B) Transmission 
electron microscopy of EVs prepared by using the PBP method (upper images) and the UC 
method (lower images). Scale bars, 200 nm. (C) Ratio of EV protein concentration per 
cellular protein concentration. 
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Table 1. List of molecular chaperones detected in OSCC-EVs.  
 
Chaperones 
MS score ratio 
(HSC-3-M3/HSC-3) 
Note 
TRAP1 / HSP75 2.95 Heat shock protein 75 kDa, mitochondrial 
HSP90AB1 / HSP90β 2.23 Heat shock protein HSP 90-beta 
HSP90AA1 / HSP90α 1.78 Heat shock protein HSP 90-alpha 
HSPH1 / HSP105 1.78 Heat shock protein 105 kDa 
HSPA1A / HSP72 1.7 Heat shock 70 kDa protein 1A 
CCT8 1.5 T-complex protein 1 subunit theta 
CCT6A 1.29 T-complex protein 1 subunit zeta 
HSPA6 / HSP70B’ 1.23 Heat shock 70 kDa protein 6 
HSPA8 / HSC70 1.23 Heat shock cognate 71 kDa protein 
CCT5 1.12 T-complex protein 1 subunit epsilon 
CCT2 1.07 T-complex protein 1 subunit beta 
TCP1 0.92 T-complex protein 1 subunit alpha 
HSPA5 / GRP78 0.85 78 kDa glucose-regulated protein 
CCT4 0.67 T-complex protein 1 subunit delta 
 
 
Table 2. Correlation between HNC stages and HSP expression levels in the tumors.  
 
 
HSP90AA1 HSP90AB1 TRAP1 HSPH1 
Stage 
Ratio 
(High / Low) 
Ratio 
(High / Low) 
Ratio 
(High / Low) 
Ratio 
(High / Low) 
Ⅰ 0.39 (7 / 18) 0.14 (3 / 22) 2.57 (18 / 7) 3.17 (19 / 6) 
Ⅱ 1.03 (35 / 34) 0.47 (22 / 47) 4.91 (54 / 11) 2.29 (48 / 21) 
Ⅲ 0.95 (38 / 40) 0.42 (23 / 55) 4.57 (64 / 14) 2.39 (55 / 23) 
Ⅳ 1.21 (142/117) 0.57 (94 / 165) 4.18 (209 / 50) 2.20 (178 / 81) 
N/A 0.74 (29 / 39) 0.26 (14 / 54) 3.25 (52 / 16) 1.83 (44 / 24) 
Total 
(n=499) 
1.01 (251 / 248) 0.45 (156 / 343) 4.05 (397 / 98) 2.22 (344 / 155) 
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Table S1. A list of siRNAs that target HSP90α, HSP90β, and CDC37 individually. 
 
Name of siRNA Note Core sequence of sense (5’ to 3’) 
siHSP90AA#1 hHSP90AA1.NM5348-415 gcugcauauuaaccuuaua 
siHSP90AA#2 hHSP90AA1.NM5348-2010 caaacauggagagaaucau 
siHSP90AB#1 hHSP90AB1-NM_001271971.1-1353 cagaagacaaggagaauua 
siHSP90AB#2 hHSP90AB1-NM_001271971.1-1754  gaagagagcaaggcaaagu 
siCDC37#1 hCDC37.NM7065-433 gcaagaaggagaagagcau 
siCDC37#2 hCDC37.NM7065-584 gaaacagaucaagcacuuu 
 
 
Table S2. Comparison of three analysis methods in terms of ratio of EV marker 
levels. 
 Western blotting LC-MS/MS ExoScreen 
HSP90α 2.04 1.78 NA 
HSP90β 1.52 2.23 NA 
EpCAM 1.27 UDL 1.25 
EGFR 2.18 UDL NA 
CD9 1.03 UDL 1.78 
GAPDH 0.96 0.91 NA 
β-actin 0.92 0.91 NA 
 
Ratios of scores (HSC-3-M3 / HSC-3) in each analytical method were shown. NA, not 
applicable. UDL, under detection limit. 
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Table S3. Correlation between 5-year survival rate and HSP expression levels in HNC 
patients. 
HSP90AA1 HSP90AB1 TRAP1 HSPH1 
Expression cut off 227.1 FPKM 552.0 FPKM 9.4 FPKM 17.6 FPKM 
5-year survival low 52% 49% 61% 54% 
5-year survival high 39% 35% 41% 41% 
Log-rank P value 0.00105 0.00115 0.0276 0.00049 
FPKM, Fragments Per Kilobase of exon per Million mapped fragments. 
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